The Clinical Difference Between the Nonfatal Patients and the Fatal Patients With Severe COVID-19

The Clinical Difference Between the Nonfatal Coronavirus Disease 2019 (COVID-19) Patients and the Fatal Cases With Severe COVID-19

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT04403009

Enrollment

100

Registered

2020-05-27

Start date

2020-02-01

Completion date

2020-06-20

Last updated

2023-03-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Character of the Severe Patients, Coronavirus Disease 2019

Brief summary

To investigate the difference of the difference between the nonfatal Coronavirus Disease 2019 (COVID-19) Patients and the fatal Patients .The cross sectional study was undertaken to compare the clinical information (laboratory and radiologic characteristics)of nonfatal participants and fatal cases. The investigators wish figure out the clinical character of the fatal participants. The result may help the physician to find the fatal patients with COVID-19 more easily. The fatal patients with COVID-19 could be treated early.

Interventions

OTHERno intervention

no intervention

Study design

Observational model

COHORT

Time perspective

CROSS_SECTIONAL

Eligibility

Sex/Gender

ALL

Age

20 Years to 100 Years

Healthy volunteers

Inclusion criteria

* The patients with Coronavirus Disease 2019 * Positive result on real-time reverse-transcriptase-polymerase-chain-reaction * Positive result on chest computed tomography

Exclusion criteria

* No

Design outcomes

Primary

Measure	Time frame	Description
IL-6	2 month	interleukin-6(mg/L)
NK cell	2 month	natural killer cell(counts/L)
PCT	2 month	procalcitonin（ng/ml）
Lymphocyte cell	2 month	the counting of Lymphocyte(counts/L)
d-dimer	2 month	d-dimer（mg/L）
PLT	2 month	the counting of Platelets（(counts/L)）
CRP	2 month	the level of C-reactive protein (mg/uL)
LDH	2 month	lactate dehydrogenase ( U/L)
CK	2 month	creatine kinase (U/L)
PT	2 month	prothrombin time(second)
ALT	2 month	alanine aminotransferase(U/L)
AST	2 month	aspartate aminotransferase(U/L)

Secondary

Measure	Time frame	Description
the clinical difference of radiologic characteristics between the fatal patients with COVID -19 and the non fatal cases	2 months	CT scan feature

Other

Measure	Time frame	Description
SPO2	2 month	oxygen Saturation

Countries

China

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026